MedTrace Logo

Estrogen, HDL, and Coronary Heart Disease in Women

NCT00083824 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 309

Last updated 2016-04-21

No results posted yet for this study

Summary

To clarify the effects of estrogen, with or without progestin, on high density lipoprotein (HDL) in postmenopausal women.

Conditions

Interventions

DRUG

Estrogens, Conjugated (USP)

0.625 mg/day QID for 3 years

DRUG

Medroxyprogesterone 17-Acetate

2.5 mg/day QID for 3 years

DRUG

Placebo

2 pills/day QID for 3 years

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Tufts University

    lead OTHER

Principal Investigators

  • Stefania Lamon-Fava · Tufts University

  • David M Herrington, MD · Wake Forest University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2007-02-28
Completion
2007-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00083824 on ClinicalTrials.gov